Orbis Medicines
PrivateLast Round
Series A
Jan 6, 2025
Total Funding Raised
$121.05M
Company Overview
Orbis Medicines operates in Healthcare & Life Sciences and is based in Frederiksberg. Its latest recorded funding round was a Series A round in January 2025.
Orbis Medicines is a biotechnology company that is developing a pipeline of oral macrocycle drugs, called 'nCycles', intended to provide oral alternatives to blockbuster biologic therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Orbis Medicines Comparables
Compare Orbis Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Curve Therapeutics | 88% | |
| Unnatural Products | 87% | |
| Vilya | 84% |
For institutional investors. Book with your work email.
Orbis Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 6, 2025 | ||||
| Seed | Feb 29, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Orbis Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| Forbion | Series A |
| New Enterprise Associates | Series A |
| Novo Holdings | Series A, Seed |
| The Export and Investment Fund of Denmark | Series A |
| Cormorant Asset Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2025
Mikael Dolsten appointed Chairperson of the Board of Directors.
- Jan 6, 2025
Morten Graugaard named new Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 27, 2026
On Oct 30th '26, Orbis Medicines ApS appoints Joanne Smith-Farrell, Ph.D., as CEO to advance its AI-driven oral macrocycle platform, immunology and inflammation programs, and partnered portfolio.
- is_developingOct 21, 2026
On Sep 22nd '26, Orbis Medicines ApS and Novo Nordisk announce a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases using Orbis Medicines ApS's AI-enabled nGen platform.
- partners_withSep 17, 2026
Orbis Medicines ApS and Novo Nordisk A/S enter a new agreement worth up to USD 1.4 billion, comprising upfront and milestone payments plus royalties tied to future sales, on Sep 17th '26.
- is_developingSep 17, 2026
Orbis Medicines ApS is developing oral therapies for cardiometabolic diseases on Sep 17th '26
- is_developingAug 20, 2026
Orbis Medicines ApS is developing a platform for oral macrocycles that combines high-throughput chemistry with computational design to help turn complex, biologic-like medicines into oral therapies, and the company raises €90 million in a 2025 Series A to advance its platform and pipeline.
For institutional investors. Book with your work email.
Orbis Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Orbis Medicines's valuation, stock price, and market status.
Is Orbis Medicines a public or private company?
Orbis Medicines is a private company.
What is the current stock price of Orbis Medicines?
Orbis Medicines is a private company, so its shares have no public market price. Caplight tracks Orbis Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Orbis Medicines worth (valuation)?
Valuation information for Orbis Medicines is not publicly available.
Can I buy Orbis Medicines stock?
Orbis Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Orbis Medicines's last funding round?
Orbis Medicines's most recent funding round was Series A on January 6, 2025.
Who are the main investors in Orbis Medicines?
Key investors in Orbis Medicines include New Enterprise Associates, Novo Holdings.
Will Orbis Medicines IPO soon?
No public IPO plans have been announced for Orbis Medicines.
How can I track Orbis Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Orbis Medicines's shares on secondary markets.